Cohance Lifesciences Limited has addressed recent market inquiries regarding the movement of its equity share price. The company confirmed that it has consistently fulfilled its disclosure obligations and that all material information, including the outcome of the April 27, 2026 board meeting, has been communicated to the stock exchanges. Management explicitly stated that there is no undisclosed information or event currently influencing the company’s market performance.
Company Stance on Market Activity
Following a recent increase in volatility and inquiries from stock exchanges, Cohance Lifesciences has moved to ensure transparency with its shareholders. The company confirmed that it remains in full compliance with all necessary disclosure requirements. Management emphasized that all significant corporate updates, most notably the outcomes from the board meeting held on April 27, 2026, have been promptly released to the public and regulatory authorities.
No Pending Material Developments
To mitigate market uncertainty, the leadership team at Cohance Lifesciences has issued a formal statement clarifying that there are no hidden events or pending corporate developments that could account for the observed changes in equity value. As of April 30, 2026, the company maintains that its current public disclosures reflect all essential information required for investors to make informed decisions regarding its market valuation.
Source: BSE
